Open Access
Nature Communications, volume 11, issue 1, publication number 1335
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours
Ellen Brenner
1
,
Barbara F. Schörg
2
,
Fatima Ahmetlić
3, 4
,
Thomas Wieder
1
,
Franz Joachim Hilke
5
,
Nadine Simon
1
,
Christopher Schroeder
5
,
German Demidov
5
,
Tanja Riedel
3
,
Birgit Fehrenbacher
1
,
Martin Schaller
1
,
Andrea Forschner
1
,
Thomas Eigentler
1
,
Heike Niessner
1
,
T. Sinnberg
1
,
Katharina S Böhm
1
,
Nadine Hömberg
3, 4
,
Heidi Braumüller
1
,
Daniel Dauch
6, 7
,
Stefan Zwirner
6
,
Lars Zender
6, 7, 8
,
Dominik Sonanini
2, 6
,
Albert Geishauser
3, 4
,
Jürgen Bauer
1
,
Martin Eichner
9
,
Katja J Ottmüller
10
,
Andreas Beilhack
10
,
Saskia Biskup
8, 11
,
Dennis Döcker
1, 11
,
Dirk Schadendorf
7, 12
,
Leticia Quintanilla-Martinez
8, 13
,
Bernd J. Pichler
2, 8
,
Manfred Kneilling
1, 2, 8
,
Ralph Mocikat
3, 4
,
Martin Röcken
1, 7, 8
7
8
Cluster of Excellence iFIT (EXC 2180) “Image Guided and Functionally Instructed Tumor Therapies”, Tübingen, Germany
|
9
11
Center for Genomics and Transcriptomics (CeGaT) GmbH and Practice for Human Genetics, Tübingen, Germany
|
Publication type: Journal Article
Publication date: 2020-03-12
Journal:
Nature Communications
scimago Q1
SJR: 4.887
CiteScore: 24.9
Impact factor: 14.7
ISSN: 20411723
General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy
Abstract
Immune checkpoint blockade (ICB)-based or natural cancer immune responses largely eliminate tumours. Yet, they require additional mechanisms to arrest those cancer cells that are not rejected. Cytokine-induced senescence (CIS) can stably arrest cancer cells, suggesting that interferon-dependent induction of senescence-inducing cell cycle regulators is needed to control those cancer cells that escape from killing. Here we report in two different cancers sensitive to T cell-mediated rejection, that deletion of the senescence-inducing cell cycle regulators p16Ink4a/p19Arf (Cdkn2a) or p21Cip1 (Cdkn1a) in the tumour cells abrogates both the natural and the ICB-induced cancer immune control. Also in humans, melanoma metastases that progressed rapidly during ICB have losses of senescence-inducing genes and amplifications of senescence inhibitors. Metastatic cells also resist CIS. Such genetic and functional alterations are infrequent in metastatic melanomas regressing during ICB. Thus, activation of tumour-intrinsic, senescence-inducing cell cycle regulators is required to stably arrest cancer cells that escape from eradication. The growth of cancer cells can be stably arrested by cytokine-induced senescence. Here, the authors show that cancers with defects in senescence-inducing cell cycle regulator pathways are resistant to immune checkpoint blockade.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.